Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings announced March 5, 2026: details in Exhibit 99.1 press release.
Atea Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings announced March 5, 2026: details in Exhibit 99.1 press release
- Clinical-stage biopharma; revenue and cash runway metrics are key investor focus given no approved products
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atea Pharmaceuticals, Inc. 8-K filings
Get the next AVIR 8-K as it lands
Follow AVIR for push alerts, or ask the research agent what this filing means.